EWTX

Edgewise Therapeutics, Inc. NASDAQ

Healthcare ·Biotechnology ·US · edgewisetx.com

$31.45

Mkt Cap $3.4B

52w Low $12.15 84.5% of range 52w High $35.00

50d MA $31.06 200d MA $22.59

P/E (TTM) -18.8x

EV/EBITDA -15.1x

P/B 6.0x

Debt/Equity 0.0x

ROE -32.1%

P/FCF -17.8x

RSI (14) —

ATR (14) —

Beta 0.25

50d MA $31.06

200d MA $22.59

Avg Volume 900.8K

About

Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The Company's lead product candidate, EDG-5506, is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy which has completed Phase 1 clinical trial. It develops a pipeli…

Recent Earnings

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Feb 26, 2026	AMC	-0.43	-0.47	-9.3%	29.66	-0.4%	+2.6%	+0.1%	-2.9%	-2.6%	-4.3%	—
Nov 6, 2025	AMC	-0.40	-0.39	+2.5%	17.09	-0.2%	+0.4%	+7.0%	+25.7%	+23.9%	+19.5%	—
Aug 7, 2025	AMC	-0.42	-0.34	+19.0%	12.95	+0.3%	-2.1%	+0.3%	+3.4%	+6.0%	+7.6%	—
May 8, 2025	AMC	-0.45	-0.43	+4.4%	14.70	+1.7%	-0.8%	+0.8%	+1.3%	-1.0%	-1.7%	—
Mar 3, 2025	AMC	-0.39	-0.42	-7.7%	25.53	-1.6%	-4.0%	+4.6%	+10.2%	+9.7%	+7.8%	—
Nov 7, 2024	AMC	-0.37	-0.36	+2.7%	35.43	-1.3%	+2.7%	-0.3%	-0.6%	-6.1%	-7.2%	—
Aug 8, 2024	AMC	-0.36	-0.34	+5.6%	16.19	+0.2%	+1.6%	+5.3%	+5.6%	+5.3%	+16.6%	—
May 9, 2024	AMC	-0.39	-0.33	+15.4%	20.00	-4.5%	-8.3%	-12.6%	-12.8%	-11.6%	-9.1%	—
Feb 22, 2024	AMC	-0.44	-0.47	-6.8%	17.37	+5.8%	-0.5%	-1.9%	-3.0%	-4.1%	-6.0%	—
Nov 9, 2023	AMC	-0.40	-0.41	-2.5%	5.72	-0.3%	-3.7%	+7.2%	+13.8%	+14.7%	+11.0%	—
Aug 10, 2023	AMC	-0.41	-0.34	+17.1%	6.74	+0.0%	-0.4%	+0.4%	+8.3%	+7.3%	+5.0%	—
May 11, 2023	AMC	-0.37	-0.36	+2.7%	9.52	-0.8%	-2.6%	-5.2%	-1.6%	-2.4%	-2.2%	—

Recent Analyst Ratings

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Mar 17	Wedbush	Maintains	Outperform → Outperform	—	$29.78	$30.41	+2.1%	+2.4%	-0.3%	+0.9%	-2.4%	+0.1%
Mar 17	JP Morgan	Maintains	Overweight → Overweight	—	$29.78	$30.41	+2.1%	+2.4%	-0.3%	+0.9%	-2.4%	+0.1%
Feb 27	Evercore ISI	Maintains	Outperform → Outperform	—	$29.66	$29.55	-0.4%	+2.6%	+0.1%	-2.9%	-2.6%	-4.3%
Nov 14	JP Morgan	Maintains	Overweight → Overweight	—	$20.42	$20.52	+0.5%	+11.4%	+9.0%	+8.5%	+9.4%	+9.0%
Nov 7	Wedbush	Maintains	Outperform → Outperform	—	$17.09	$17.05	-0.2%	+0.4%	+7.0%	+25.7%	+23.9%	+19.5%
Nov 7	RBC Capital	Maintains	Outperform → Outperform	—	$17.09	$17.05	-0.2%	+0.4%	+7.0%	+25.7%	+23.9%	+19.5%
Aug 19	JP Morgan	Maintains	Overweight → Overweight	—	$14.00	$14.02	+0.1%	-1.4%	-1.1%	+4.4%	+6.1%	+2.1%
Aug 8	RBC Capital	Maintains	Outperform → Outperform	—	$12.95	$12.99	+0.3%	-2.1%	+0.3%	+3.4%	+6.0%	+7.6%
Jun 5	RBC Capital	Maintains	Outperform → Outperform	—	$14.49	$14.47	-0.1%	+2.3%	+5.2%	+5.3%	+6.6%	+8.7%
May 16	JP Morgan	Maintains	Overweight → Overweight	—	$14.45	$14.48	+0.2%	+2.3%	+2.4%	+2.9%	+1.0%	-3.0%
May 9	RBC Capital	Maintains	Outperform → Outperform	—	$14.70	$14.95	+1.7%	-0.8%	+0.8%	+1.3%	-1.0%	-1.7%
Apr 21	Wedbush	Maintains	Outperform → Outperform	—	$13.45	$13.36	-0.7%	-1.1%	+0.6%	+10.3%	+14.5%	+10.3%
Apr 3	RBC Capital	Maintains	Outperform → Outperform	—	$15.52	$14.90	-4.0%	-12.5%	-25.8%	-23.8%	-26.0%	-19.5%
Apr 3	Scotiabank	Downgrade	Sector Outperform → Sector Perform	—	$15.52	$14.90	-4.0%	-12.5%	-25.8%	-23.8%	-26.0%	-19.5%
Apr 2	Piper Sandler	Maintains	Overweight → Overweight	—	$20.13	$14.50	-28.0%	-22.9%	-32.5%	-42.8%	-41.2%	-42.9%
Mar 4	RBC Capital	Maintains	Outperform → Outperform	—	$25.53	$25.12	-1.6%	-4.0%	+4.6%	+10.2%	+9.7%	+7.8%
Dec 17	Evercore ISI	Maintains	Outperform → Outperform	—	$32.69	$33.37	+2.1%	-7.7%	-8.2%	-5.8%	-5.8%	-8.3%
Nov 27	Truist	Maintains	Buy → Buy	—	$32.08	$33.16	+3.4%	+0.4%	+2.9%	-1.7%	-0.4%	-0.1%
Nov 8	Wedbush	Maintains	Outperform → Outperform	—	$35.43	$34.96	-1.3%	+2.7%	-0.3%	-0.6%	-6.1%	-7.2%
Oct 11	Piper Sandler	Maintains	Overweight → Overweight	—	$29.99	$29.99	+0.0%	+6.4%	+6.1%	+10.0%	+16.8%	+18.4%
Sep 20	RBC Capital	Maintains	Outperform → Outperform	—	$29.50	$29.94	+1.5%	-4.1%	-10.2%	-12.1%	-12.3%	-11.9%
Sep 19	Truist	Maintains	Buy → Buy	—	$19.07	$25.75	+35.0%	+54.7%	+48.3%	+38.9%	+35.9%	+35.7%
Sep 17	RBC Capital	Maintains	Outperform → Outperform	—	$16.86	$17.11	+1.5%	+7.2%	+13.1%	+75.0%	+67.7%	+57.1%
Aug 16	Wedbush	Maintains	Outperform → Outperform	—	$18.87	$18.88	+0.1%	-2.2%	-0.3%	+4.5%	+11.0%	+3.8%
Aug 12	JP Morgan	Maintains	Overweight → Overweight	—	$16.45	$16.50	+0.3%	+3.6%	+3.9%	+3.6%	+14.7%	+12.2%
Jul 25	RBC Capital	Maintains	Outperform → Outperform	—	$21.18	$21.29	+0.5%	-11.6%	-10.4%	-14.9%	-19.5%	-19.6%
Jul 10	RBC Capital	Maintains	Outperform → Outperform	—	$22.85	$22.92	+0.3%	-5.8%	-2.3%	-1.9%	+0.1%	-2.8%
Jul 9	JP Morgan	Maintains	Overweight → Overweight	—	$20.92	$21.00	+0.4%	+9.2%	+2.9%	+6.7%	+7.2%	+9.3%
Jul 1	Piper Sandler	Maintains	Overweight → Overweight	—	$18.01	$17.99	-0.1%	+7.6%	+2.1%	+1.5%	+7.9%	+16.2%
Jun 26	Wedbush	Maintains	Outperform → Outperform	—	$17.39	$17.77	+2.2%	+0.5%	+0.6%	+3.6%	+11.4%	+5.7%
Apr 22	RBC Capital	Maintains	Outperform → Outperform	—	$15.23	$15.93	+4.6%	-1.0%	+2.8%	+5.8%	+4.7%	+6.2%
Apr 17	Truist	Maintains	Buy → Buy	—	$16.63	$16.85	+1.3%	-5.9%	-7.1%	-8.4%	-9.3%	-5.9%
Apr 16	Wedbush	Maintains	Outperform → Outperform	—	$16.48	$16.28	-1.2%	+0.9%	-5.0%	-6.2%	-7.6%	-8.5%
Mar 12	RBC Capital	Maintains	Outperform → Outperform	—	$16.75	$16.73	-0.1%	+5.8%	+3.9%	+1.9%	+1.0%	-7.3%
Nov 10	Wedbush	Maintains	Outperform → Outperform	—	$5.72	$5.70	-0.3%	-3.7%	+7.2%	+13.8%	+14.7%	+11.0%
Aug 16	Wedbush	Maintains	Outperform → Outperform	—	$7.30	$7.24	-0.8%	-1.0%	-3.0%	-1.5%	-0.4%	+0.1%
Aug 11	Wedbush	Maintains	Outperform → Outperform	—	$6.74	$6.74	+0.0%	-0.4%	+0.4%	+8.3%	+7.3%	+5.0%
Jun 30	JP Morgan	Maintains	Overweight → Overweight	—	$7.53	$7.98	+6.0%	+2.9%	+0.1%	+1.7%	-1.3%	-3.2%
Jun 28	RBC Capital	Maintains	Outperform → Outperform	—	$7.51	$7.95	+5.9%	+0.7%	+0.3%	+3.2%	+0.4%	+2.0%
Jun 28	Truist	Maintains	Buy → Buy	—	$7.51	$7.95	+5.9%	+0.7%	+0.3%	+3.2%	+0.4%	+2.0%
Jun 27	Truist	Maintains	Buy → Buy	—	$6.86	$6.88	+0.3%	+9.5%	+10.2%	+9.8%	+13.0%	+9.9%
Jun 20	JP Morgan	Maintains	Overweight → Overweight	—	$8.30	$7.96	-4.1%	-1.3%	-4.0%	-5.7%	-8.4%	-17.3%
May 16	JP Morgan	Maintains	Overweight → Overweight	—	$9.02	$8.86	-1.8%	+3.8%	+3.0%	+3.2%	+1.7%	+7.4%
May 12	Wedbush	Maintains	Outperform → Outperform	—	$9.52	$9.44	-0.8%	-2.6%	-5.2%	-1.6%	-2.4%	-2.2%
Feb 28	JP Morgan	Maintains	Overweight → Overweight	—	$9.44	$9.43	-0.1%	+1.5%	+1.6%	-0.8%	-0.1%	-6.8%
Nov 4	RBC Capital	Maintains	Outperform → Outperform	—	$10.04	$10.27	+2.3%	-4.7%	-4.5%	-4.4%	-6.4%	+4.5%
Aug 25	Goldman Sachs	Downgrade	Neutral → Sell	—	$11.02	$9.52	-13.6%	-7.4%	-11.0%	-8.6%	-9.4%	-8.5%
May 24	Goldman Sachs	Maintains	Neutral → Neutral	—	$7.27	$7.13	-1.9%	-12.7%	-22.0%	-20.8%	-16.5%	-14.0%
May 12	SVB Leerink	Maintains	Outperform → Outperform	—	$7.07	$6.94	-1.8%	+5.7%	+10.7%	+3.1%	+4.4%	+2.7%
May 12	Goldman Sachs	Maintains	Neutral → Neutral	—	$7.07	$6.94	-1.8%	+5.7%	+10.7%	+3.1%	+4.4%	+2.7%

Recent Filings

8-K

Edgewise Therapeutics, Inc. -- 8-K Filing

Edgewise Therapeutics reported strong 2025 financial results and execution, positioning the company for transformative growth in the upcoming year.

Feb 26

Data updated apr 25, 2026 8:07am · Source: massive.com